Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAME Study of colchicine in chronic-phase adult-onset Still's disease and ANCA-associated vasculitis
jRCTs031250775Recruiting
- Start
- Aug 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of colchicine in adult-onset Still's disease (AOSD) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Primary endpoint: Feasibility and severe treatment-related adverse events at 12 weeks. Started Aug 2026; status: recruiting.
02
Drugs
colchicine
03
Conditions
adult-onset Still's disease (AOSD)anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on jRCTs031250775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250775.